M&A / Acquisition · GCC · Announced 12 Jul 2026
Bausch Health → AUG Pharma
M&A / Acquisition deal between Bausch Health (Canada) and AUG Pharma (Egypt), announced 12 Jul 2026. Value: Undisclosed.
Parties: Bausch Health (Canada) → AUG Pharma (Egypt)
- Deal type
- M&A / Acquisition
- Value
- Undisclosed
- Territory
- GCC + MENA (UAE production & registration base; KSA the largest market in the portfolio)
- Therapeutic area
- Infectious Disease
- Asset
- MEDPHARMA UAE LLC ~67 generic products (portfolio → 380+); UAE manufacturing plant: OSD, semi-solids, creams/liquids; ~17-country export network
- Announced
- 12 Jul 2026
Our analysis
Why this matters
AUG didn't just buy access, it bought a Gulf factory. For twenty years Egyptian pharma reached the Gulf the slow way: direct export, or a single-country Saudi greenfield built over years (EVA's route).
AUG used the M&A engine to leap both — and the addition of the plant is what elevates this from a smart distribution play to a genuine platform move. In one transaction AUG acquired registered market access and in-region manufacturing across OSD, semi-solids and creams/liquids.
The full analysis is free to read with a work email on this page.
Source: Signalbase